PortfoliosLab logoPortfoliosLab logo
CHRS vs. AG
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CHRS vs. AG - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Coherus BioSciences, Inc. (CHRS) and First Majestic Silver Corp. (AG). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CHRS achieves a 3.52% return, which is significantly lower than AG's 18.81% return. Over the past 10 years, CHRS has underperformed AG with an annualized return of -22.28%, while AG has yielded a comparatively higher 5.48% annualized return.


CHRS

1D
-3.29%
1M
-15.03%
YTD
3.52%
6M
20.49%
1Y
87.98%
3Y*
-30.87%
5Y*
-35.60%
10Y*
-22.28%

AG

1D
-5.81%
1M
2.11%
YTD
18.81%
6M
26.15%
1Y
181.03%
3Y*
49.83%
5Y*
2.67%
10Y*
5.48%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CHRS vs. AG - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
CHRS
Coherus BioSciences, Inc.
3.52%2.90%-58.56%-57.95%-50.38%-8.17%-3.47%98.95%2.84%-68.74%
AG
First Majestic Silver Corp.
18.81%204.32%-10.47%-25.99%-24.73%-17.24%9.62%108.15%-12.61%-11.66%

Correlation

The correlation between CHRS and AG is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.23

Correlation (3Y)
Calculated over the trailing 3-year period

0.20

Correlation (5Y)
Calculated over the trailing 5-year period

0.21

Correlation (10Y)
Calculated over the trailing 10-year period

0.15

Correlation (All Time)
Calculated using the full available price history since Nov 7, 2014

0.13

Fundamentals

Market Cap

CHRS:

$200.51M

AG:

$9.92B

EPS

CHRS:

$1.52

AG:

$0.60

PE Ratio

CHRS:

0.96

AG:

33.16

PS Ratio

CHRS:

3.83

AG:

6.54

PB Ratio

CHRS:

2.55

AG:

3.41

Total Revenue (TTM)

CHRS:

$46.88M

AG:

$1.49B

Gross Profit (TTM)

CHRS:

$23.41M

AG:

$646.49M

EBITDA (TTM)

CHRS:

-$162.15M

AG:

$824.25M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CHRS vs. AG — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CHRS
CHRS Risk / Return Rank: 7272
Overall Rank
CHRS Sharpe Ratio Rank: 7373
Sharpe Ratio Rank
CHRS Sortino Ratio Rank: 7272
Sortino Ratio Rank
CHRS Omega Ratio Rank: 6969
Omega Ratio Rank
CHRS Calmar Ratio Rank: 7575
Calmar Ratio Rank
CHRS Martin Ratio Rank: 7171
Martin Ratio Rank

AG
AG Risk / Return Rank: 8787
Overall Rank
AG Sharpe Ratio Rank: 9191
Sharpe Ratio Rank
AG Sortino Ratio Rank: 8686
Sortino Ratio Rank
AG Omega Ratio Rank: 8484
Omega Ratio Rank
AG Calmar Ratio Rank: 8888
Calmar Ratio Rank
AG Martin Ratio Rank: 8686
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CHRS vs. AG - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Coherus BioSciences, Inc. (CHRS) and First Majestic Silver Corp. (AG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


CHRSAGDifference
Sharpe ratioReturn per unit of total volatility

-1.40

Sortino ratioReturn per unit of downside risk

-0.97

Omega ratioGain probability vs. loss probability

1.22

1.35

-0.13

Calmar ratioReturn relative to maximum drawdown

2.13

4.24

-2.11

Martin ratioReturn relative to average drawdown

3.95

9.46

-5.51

CHRS vs. AG - Sharpe Ratio Comparison

The current CHRS Sharpe Ratio is 1.09, which is lower than the AG Sharpe Ratio of 2.49. The chart below compares the historical Sharpe Ratios of CHRS and AG, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


CHRSAGDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.09

2.49

-1.40

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.42

0.04

-0.47

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.30

0.09

-0.39

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.23

0.05

-0.27

Drawdowns

CHRS vs. AG - Drawdown Comparison

The maximum CHRS drawdown since its inception was -98.21%, which is greater than AG's maximum drawdown of -90.20%. Use the drawdown chart below to compare losses from any high point for CHRS and AG.


Loading charts...

Drawdown Indicators


CHRSAGDifference

Max Drawdown

Largest peak-to-trough decline

-98.21%

-90.20%

-8.01%

Max Drawdown (1Y)

Largest decline over 1 year

-41.43%

-42.92%

+1.49%

Max Drawdown (3Y)

Largest decline over 3 years

-87.71%

-42.92%

-44.79%

Max Drawdown (5Y)

Largest decline over 5 years

-96.47%

-76.89%

-19.58%

Max Drawdown (10Y)

Largest decline over 10 years

-97.88%

-80.82%

-17.06%

Current Drawdown

Current decline from peak

-96.08%

-38.18%

-57.90%

Average Drawdown

Average peak-to-trough decline

-63.48%

-59.21%

-4.27%

Ulcer Index

Depth and duration of drawdowns from previous peaks

22.36%

19.23%

+3.13%

Volatility

CHRS vs. AG - Volatility Comparison

The current volatility for Coherus BioSciences, Inc. (CHRS) is 21.11%, while First Majestic Silver Corp. (AG) has a volatility of 22.62%. This indicates that CHRS experiences smaller price fluctuations and is considered to be less risky than AG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CHRSAGDifference

Volatility (1M)

Calculated over the trailing 1-month period

21.11%

22.62%

-1.51%

Volatility (6M)

Calculated over the trailing 6-month period

60.22%

56.05%

+4.17%

Volatility (1Y)

Calculated over the trailing 1-year period

81.15%

73.23%

+7.92%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

84.64%

61.33%

+23.31%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

74.90%

61.84%

+13.06%

Dividends

CHRS vs. AG - Dividend Comparison

CHRS has not paid dividends to shareholders, while AG's dividend yield for the trailing twelve months is around 0.18%.


PositionTTM20252024202320222021
AG
First Majestic Silver Corp.
0.18%0.12%0.33%0.34%0.31%0.14%
CHRS
Coherus BioSciences, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%

Financials

CHRS vs. AG - Financials Comparison

This section allows you to compare key financial metrics between Coherus BioSciences, Inc. and First Majestic Silver Corp.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00100.00M200.00M300.00M400.00M500.00M20222023202420252026
12.31M
470.07M
(CHRS) Total Revenue
(AG) Total Revenue
Values in USD except per share items

Frequently Asked Questions


CHRS and AG have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AG has higher volatility (22.62%) compared to CHRS (21.11%). In terms of maximum drawdown, CHRS dropped -98.21% vs AG's -90.20%.

AG currently has the higher Sharpe Ratio (2.49 vs 1.09), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CHRS and AG

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer